Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation - Top-Institutions - MDSpire

Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation

  • By

  • Li Huang

  • Riping Xu

  • Junyu Fan

  • Liangqing Zhang

  • Min Chen

  • May 28, 2026

  • 0 min

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Massachusetts General Hospital
    Massachusetts General Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology
    • Cardiovascular Research

  • #2

    Brigham and Women’s Hospital
    Brigham and Women’s Hospital

    Boston, Massachusetts

    Key Differentiators

    • Cardiology
    • Cardiac Surgery

  • #3

    CONDI2/ERIC-PPCI trial
    CONDI2/ERIC-PPCI trial

    N/A, N/A

    Key Differentiators

    • Clinical Trials
    • Cardiology

  • #4

    Jackson Heart Study
    Jackson Heart Study

    Jackson, Mississippi

    Key Differentiators

    • Cardiovascular Research

  • #5

    University Hospitals Cleveland Medical Center
    University Hospitals Cleveland Medical Center

    Cleveland, Ohio

    Key Differentiators

    • Cardiology
    • Cardiovascular Care

Original Source(s)

Targeting the heart-immune axis after myocardial infarction: from inflammation to immunomodulation

  • by Li Huang, Riping Xu, Junyu Fan, Liangqing Zhang, Min Chen

  • May 28, 2026

Related Content

Residual inflammatory risk post STEMI: high prevalence despite LDL-C control and association with other secondary prevention targets

Use of PCSK9 Inhibitors Among Patients Receiving Immune Checkpoint Inhibitors for Cancer

The association between time-weighted cumulative life's essential 8 and aortic valve calcification